Physicians' Academy for Cardiovascular Education

Residual risk and HDL-cholesterol:

Slides (presentation) - Oct. 5, 2012

Residual risk and HDL-cholesterol: What are the current perspectives?

Selection of slides prepared & presented by:
Prof. Erik Stroes, MD
Department of vascular medicine, Academic Medical Centre, Amsterdam
at PACE Lipid Master Class
Budapest, September 21-22, 2012

View presentation, click on images

Residual risk and HDL-cholesterol
Is There a Therapeutic Need
Selecting ‘promising’ candidates
HDL(-c) is ‘a mixed bag
Many ways to increase HDL-c
Outline HDL-c and CV-protection
Quantity versus Quality
HDL Increases Cholesterol Flux
Static versus Dynamic
HDL protection beyond RCT
HDL Improves Endothelial Function
HDL: carrier or carrier-‘platform‘ ?
Summary I protective mechanisms
Epidemiology versus Genetics LDL vs HDL
Summary II Epidemiology vs Genetics
‘Negative’ HDLc trials Revisited
Reasons for adverse outcome Torcetrapib
Off-target effects of Torcetrapib
Why did dalcetrapib fail
Other CETP-Inhibitors
Lessons HDLc-increasing trials
Therapies on the Horizon
Targeting cholesterol ‘flux’ by increasing ApoA-I
Indications for ‘apo-AI/HDL infusables’
Take Home:

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.

Share this page with your colleagues and friends: